Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

  • Ribera, Josep-Maria
  • Morgades, Mireia
  • Ribera, Jordi
  • Montesinos, Pau
  • Cano-Ferri, Isabel
  • López Martínez, Pilar
  • Esteve, Jordi
  • Esteban, Daniel
  • García-Fortes, María
  • Alonso, Natalia
  • González-Campos, José
  • Bermúdez, Arancha
  • Torrent, Anna
  • Genescà, Eulàlia
  • Maluquer, Clara
  • Martínez-López, Joaquín
  • García-Sanz, Ramón
This project was supported in part by the ISCIII (PI14/01971 and PI19/01828), co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future,” CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/“La Caixa.” This project has also been supported by Incyte Biosciences International S.a.r.l. with study medication and financial support. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the “European Union's Horizon 2020 research and innovation and EFPIA.”, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: results of the ALLRE08 PETHEMA trial

  • Ribera, Josep-Maria
  • Tormo, Mar
  • Martínez-Carballeira, Daniel
  • González-Campos, José
  • Barba Suñol, Pere
  • Montesinos, Pau
  • Morgades, Mireia
Leucèmia limfoblàstica aguda; Adolescents i adults joves; Tractament pediàtric, Leucemia linfoblástica aguda; Adolescentes y adultos jóvenes; Tratamiento pediátrico, Acute lymphoblastic leukemia; Adolescents and young adults; Pediatric treatment, Background Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). Methods This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. Results From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). Conclusion A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior., Supported in part by grants PI14/01971 from Fondo de Investigaciones Sanitarias, Instituto Carlos III, SGR288 (GRC) Generalitat de Catalunya, Fundació La Caixa and CIBERONC (JMHR and AO).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Ferrer Oliveras, Albert
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Genescà, Eulàlia|||0000-0002-5657-4842
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE ®) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated lysis. In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin's lymphomas, but the most important trials have been conducted in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and in ALL with minimal residual disease. Encouraging reports on the activity of blinatumomab in R/R Philadelphia chromosome-negative B-cell precursor ALL led to its approval by the US Food and Drug Administration on December 3, 2014 after an accelerated review process. This review focuses on the profile of blinatumomab and its activity in R/R ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, Results of the ALLRE08 PETHEMA trial

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • González Campos, José
  • Gil, Cristina
  • Barba, Pere|||0000-0001-7076-7969
  • García-Boyero, Raimundo|||0000-0001-9473-1004
  • Coll, Rosa|||0000-0003-0560-1254
  • Pedreño, María
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Novo, Andrés
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Calbacho, Maria|||0000-0001-8106-4863
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Sánchez-Sánchez, María-José
  • Cervera, Marta
  • Feliu Frasnedo, Evarist|||0000-0001-5780-3136
  • Orfao, Alberto|||0000-0002-0007-7230
Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior. A full pediatric trial is feasible and effective for adolescent and young adults with acute lymphoblastic leukemia, with better results for adolescents than for young adults. The outcome of patients showing poor early response was not significantly inferior than that observed for good responders after being transferred to a high-risk trial.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse

  • Forero-Castro, Maribel
  • Montaño, Adrián|||0000-0002-3178-6726
  • Robledo, Cristina|||0000-0003-0445-3210
  • García de Coca, Alfonso
  • Fuster, José Luis|||0000-0002-4881-9440
  • De las Heras, Natalia|||0000-0002-5188-5350
  • Queizán, José Antonio
  • Hernández-Sánchez, María|||0000-0001-9968-2782
  • Corchete Sánchez, Luis Antonio|||0000-0003-4577-8599
  • Martín-Izquierdo, Marta
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Benito, Rocío|||0000-0001-9781-4198
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
The clonal basis of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is complex and not fully understood. Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) were carried out in matched diagnosis-relapse samples from 13 BCP-ALL patients to identify patterns of genetic evolution that could account for the phenotypic changes associated with disease relapse. The integrative genomic analysis of aCGH, MLPA and NGS revealed that 100% of the BCP-ALL patients showed at least one genetic alteration at diagnosis and relapse. In addition, there was a significant increase in the frequency of chromosomal lesions at the time of relapse (p = 0.019). MLPA and aCGH techniques showed that IKZF1 was the most frequently deleted gene. TP53 was the most frequently mutated gene at relapse. Two TP53 mutations were detected only at relapse, whereas the three others showed an increase in their mutational burden at relapse. Clonal evolution patterns were heterogeneous, involving the acquisition, loss and maintenance of lesions at relapse. Therefore, this study provides additional evidence that BCP-ALL is a genetically dynamic disease with distinct genetic profiles at diagnosis and relapse. Integrative NGS, aCGH and MLPA analysis enables better molecular characterization of the genetic profile in BCP-ALL patients during the evolution from diagnosis to relapse.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The yin and yang-like clinical implications of the cdkn2a/arf/cdkn2b gene cluster in acute lymphoblastic leukemia

  • González Gil, Celia|||0000-0002-7582-1482
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Acute lymphoblastic leukemia (ALL) is a malignant clonal expansion of lymphoid hematopoietic precursors that exhibit developmental arrest at varying stages of differentiation. Similar to what occurs in solid cancers, transformation of normal hematopoietic precursors is governed by a multistep oncogenic process that drives initiation, clonal expansion and metastasis. In this process, alterations in genes encoding proteins that govern processes such as cell proliferation, differentiation, and growth provide us with some of the clearest mechanistic insights into how and why cancer arises. In such a scenario, deletions in the 9p21.3 cluster involving CDKN2A/ARF/CDKN2B genes arise as one of the oncogenic hallmarks of ALL. Deletions in this region are the most frequent structural alteration in T-cell acute lymphoblastic leukemia (T-ALL) and account for roughly 30% of copy number alterations found in B-cell-precursor acute lymphoblastic leukemia (BCP-ALL). Here, we review the literature concerning the involvement of the CDKN2A/B genes as a prognosis marker of good or bad response in the two ALL subtypes (BCP-ALL and T-ALL). We compare frequencies observed in studies performed on several ALL cohorts (adult and child), which mainly consider genetic data produced by genomic techniques. We also summarize what we have learned from mouse models designed to evaluate the functional involvement of the gene cluster in ALL development and in relapse/resistance to treatment. Finally, we examine the range of possibilities for targeting the abnormal function of the protein-coding genes of this cluster and their potential to act as anti-leukemic agents in patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Gil, Cristina
  • Guàrdia, Ramón
  • Moreno, Maria José
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • González Campos, José
  • González Gil, Celia|||0000-0002-7582-1482
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Ramirez, Jose Luis
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Artola, Maria Teresa
  • Cladera, Antonia
  • Tormo, Mar|||0000-0001-9622-1649
  • Bermúdez, Arancha
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Novo, Andrés
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Junca, Jordi|||0000-0003-0142-772X
  • Ciudad Pizarro, Juana
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Genescà, Eulàlia|||0000-0002-5657-4842
The concurrent administration of tyrosine kinase inhibitors (TKIs) with standard chemotherapy together with allogeneic hematopoietic stem cell transplantation (alloHSCT) has improved the outcome of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Although to date, no study has shown alloHSCT to be inferior to chemotherapy plus TKIs in any subgroup of adult Ph+ ALL, there is some evidence suggesting no additional benefit of alloHSCT in patients with deep molecular responses to intensive chemotherapy with a second-generation, and especially, third-generation TKI. As none of these positive and negative studies are controlled, randomized trials are needed to fully define the role of alloHSCT in Ph+ ALL, especially in those with deep molecular response. However, if studies combining TKIs with new approaches such as immunotherapy lead to durable responses, alloHSCT in the first complete remission could be avoided in the near future in the majority of patients with Ph+ ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • García-Calduch, Olga
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Montesinos, Pau|||0000-0002-3275-5593
  • Cano-Ferri, Isabel
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • García Fortes, María|||0000-0002-0959-9449
  • Alonso Vence, Natalia
  • González Campos, José
  • Bermúdez, Arancha
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Martínez-Lopez, Joaquín
  • García-Sanz, Ramón|||0000-0003-4120-2787
Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph + ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P =.002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph + ALL. Cross-trial comparison suggests improvement vs imatinib (clinicaltrials.gov identifier #NCT02776605).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, Long-term results

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Morgades, Mireia|||0000-0003-0295-2534
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Montesinos, Pau|||0000-0002-3275-5593
  • Cano-Ferri, Isabel
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • García Fortes, María|||0000-0002-0959-9449
  • Alonso, Natalia
  • González Campos, José
  • Bermúdez, Arancha
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Maluquer, Clara
  • Martínez-López, José
  • García-Sanz, Ramón|||0000-0003-4120-2787
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: results of the ALLRE08 PETHEMA trial

  • Ribera, Josep-Maria
  • Tormo, Mar
  • Martínez-Carballeira, Daniel
  • González-Campos, José
  • Barba Suñol, Pere
  • Montesinos, Pau
  • Morgades, Mireia
Leucèmia limfoblàstica aguda; Adolescents i adults joves; Tractament pediàtric, Leucemia linfoblástica aguda; Adolescentes y adultos jóvenes; Tratamiento pediátrico, Acute lymphoblastic leukemia; Adolescents and young adults; Pediatric treatment, Background Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). Methods This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. Results From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). Conclusion A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior., Supported in part by grants PI14/01971 from Fondo de Investigaciones Sanitarias, Instituto Carlos III, SGR288 (GRC) Generalitat de Catalunya, Fundació La Caixa and CIBERONC (JMHR and AO).